425 related articles for article (PubMed ID: 26907255)
1. Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells.
Kawser Hossain M; Abdal Dayem A; Han J; Kumar Saha S; Yang GM; Choi HY; Cho SG
Int J Mol Sci; 2016 Feb; 17(2):256. PubMed ID: 26907255
[TBL] [Abstract][Full Text] [Related]
2. iPSC technology-based regenerative therapy for diabetes.
Kondo Y; Toyoda T; Inagaki N; Osafune K
J Diabetes Investig; 2018 Mar; 9(2):234-243. PubMed ID: 28609558
[TBL] [Abstract][Full Text] [Related]
3. Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing.
Yin X; Li Q; Shu Y; Wang H; Thomas B; Maxwell JT; Zhang Y
J Biomed Sci; 2024 May; 31(1):47. PubMed ID: 38724973
[TBL] [Abstract][Full Text] [Related]
4. Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery.
Qian L; Tcw J
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530458
[TBL] [Abstract][Full Text] [Related]
5. Modeling different types of diabetes using human pluripotent stem cells.
Abdelalim EM
Cell Mol Life Sci; 2021 Mar; 78(6):2459-2483. PubMed ID: 33242105
[TBL] [Abstract][Full Text] [Related]
6. Recent technological updates and clinical applications of induced pluripotent stem cells.
Diecke S; Jung SM; Lee J; Ju JH
Korean J Intern Med; 2014 Sep; 29(5):547-57. PubMed ID: 25228828
[TBL] [Abstract][Full Text] [Related]
7. Generation and selection of pluripotent stem cells for robust differentiation to insulin-secreting cells capable of reversing diabetes in rodents.
Southard SM; Kotipatruni RP; Rust WL
PLoS One; 2018; 13(9):e0203126. PubMed ID: 30183752
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research.
Hosokawa Y; Hanafusa T; Imagawa A
J Diabetes Investig; 2019 Sep; 10(5):1158-1164. PubMed ID: 31161717
[TBL] [Abstract][Full Text] [Related]
9. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease.
Chun YS; Chaudhari P; Jang YY
Int J Biol Sci; 2010 Dec; 6(7):796-805. PubMed ID: 21179587
[TBL] [Abstract][Full Text] [Related]
10. Modeling HNF1B-associated monogenic diabetes using human iPSCs reveals an early stage impairment of the pancreatic developmental program.
El-Khairi R; Olszanowski E; Muraro D; Madrigal P; Tilgner K; Chhatriwala M; Vyas S; Chia CY; Vallier L; Rodríguez-Seguí SA
Stem Cell Reports; 2021 Sep; 16(9):2289-2304. PubMed ID: 34450036
[TBL] [Abstract][Full Text] [Related]
11. Generation of Hepatobiliary Cell Lineages from Human Induced Pluripotent Stem Cells: Applications in Disease Modeling and Drug Screening.
Pasqua M; Di Gesù R; Chinnici CM; Conaldi PG; Francipane MG
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360991
[TBL] [Abstract][Full Text] [Related]
12. Human pluripotent stem cell-derived models and drug screening in CNS precision medicine.
Silva MC; Haggarty SJ
Ann N Y Acad Sci; 2020 Jul; 1471(1):18-56. PubMed ID: 30875083
[TBL] [Abstract][Full Text] [Related]
13. Application Prospect of Induced Pluripotent Stem Cells in Organoids and Cell Therapy.
Zhang T; Qian C; Song M; Tang Y; Zhou Y; Dong G; Shen Q; Chen W; Wang A; Shen S; Zhao Y; Lu Y
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473926
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the induced pluripotent stem cell-based skin regeneration.
Choudhury S; Surendran N; Das A
Wound Repair Regen; 2021 Sep; 29(5):697-710. PubMed ID: 33970525
[TBL] [Abstract][Full Text] [Related]
15. Harnessing Human Pluripotent Stem Cell-Derived Pancreatic In Vitro Models for High-Throughput Toxicity Testing and Diabetes Drug Discovery.
Ching C; Iich E; Teo AKK
Handb Exp Pharmacol; 2023; 281():301-332. PubMed ID: 37306817
[TBL] [Abstract][Full Text] [Related]
16. Genome Editing Human Pluripotent Stem Cells to Model β-Cell Disease and Unmask Novel Genetic Modifiers.
George MN; Leavens KF; Gadue P
Front Endocrinol (Lausanne); 2021; 12():682625. PubMed ID: 34149620
[TBL] [Abstract][Full Text] [Related]
17. Monogenic Diabetes Modeling:
Burgos JI; Vallier L; Rodríguez-Seguí SA
Front Endocrinol (Lausanne); 2021; 12():692596. PubMed ID: 34295307
[TBL] [Abstract][Full Text] [Related]
18. Stem Cells Reprogramming in Diabetes Mellitus and Diabetic Complications: Recent Advances.
Madkor HR; Abd El-Aziz MK; Abd El-Maksoud MS; Ibrahim IM; Ali FEM
Curr Diabetes Rev; 2024 Jan; ():. PubMed ID: 38173073
[TBL] [Abstract][Full Text] [Related]
19. Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy.
Dai S; Qiu L; Veeraraghavan VP; Sheu CL; Mony U
Curr Stem Cell Res Ther; 2024; 19(6):809-819. PubMed ID: 37291782
[TBL] [Abstract][Full Text] [Related]
20. Overcoming the challenges of scalable iPSC generation in translation medicine.
Liu DH; Tseng HC; Lee MS; Chiou GY; Wang CT; Lin YY; Lai WY; Liu YH; Wang CY; Lee CY; Kao CL; Chen CF; Chien Y
J Chin Med Assoc; 2024 Feb; 87(2):163-170. PubMed ID: 38132887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
